understanding the r&d landscape
DESCRIPTION
The Power of Vaccines: ‘getting to zero’ for HIV and TB was an event hosted by the TB/HIV and Prevention Working Groups of the UK Consortium on AIDS and International Development. The meeting was sponsored by Pamela Nash MP and held on Friday, 18th May 2012, in Portcullis House, Westminster. Read more at http://storify.com/PamojaUK/the-power-of-vaccineshttp://www.pamoja.uk.comTRANSCRIPT
The Power of Vaccines: ‘getting to zero’ for HIV and TB Understanding the R&D funding landscape
Roni Liyanage Senior Policy Analyst [email protected]
Outline
• About Policy Cures • About G-FINDER • Neglected disease R&D funding • Vaccine R&D funding • HIV & TB vaccine funding
• Key messages
About Policy Cures
Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the developing world
<INSERT PICTURE>
About G-FINDER
WHO/MALI
• An annual funding survey (2007, 2008, 2009, 2010) – 31 neglected diseases
– 134 product areas
– All R&D stages
• Over 8,000 entries per year – Data from 54 countries
– Data from 240 organisations
• Funded by the Bill & Melinda Gates Foundation
Neglected Disease R&D Funding
Total Neglected Disease R&D funding
$3,063 million invested in neglected disease R&D in 2010
↓$109m (-3.5%)
$0
$500
$1,000
$1,500
$2,000
$2,500
$3,000
$3,500
2007 2008 2009 2010
Mill
ion
s
HIV/AIDS
$1.07 BILLION Total spend on HIV/AIDS R&D in 2010
35% of Global ND R&D funding
HIV & TB R&D funding
TB
$575.4 MILLION Total spend on TB R&D in 2010
18.8% of Global ND R&D funding
$-
$200
$400
$600
$800
$1,000
$1,200
2007 2008 2009 2010
Mill
ion
s
HIV
TB
Vaccine R&D Funding
Vaccine R&D funding
$0
$200
$400
$600
$800
$1,000
$1,200
$1,400
2007 2008 2009 2010
Mill
ion
s
Public funding Industry funding Philanthropic funding
62% Public funding
20% Industry funding
17% Philanthropic funding
Vaccine R&D funding
Other 4% Bacterial
Pneumonia & Meningitis 7%
Diarrhoeal diseases 7%
Malaria 8%
TB 9%
Dengue 10%
HIV/AIDS 55%
Top funders of neglected disease vaccine R&D, 2010
1 NIH $509m 2 Pharmaceutical Industry $223m
3 Bill & Melinda Gates Foundation $176m 4 U S D e p a r t m e n t o f D e f e n s e ( D O D ) $ 4 3 m
5 US Agency for International Development (USAID) $33m
6 UK Department for International Development (DFID) $30m
7 E u r o p e a n C o m m i s s i o n : R e s e a r c h D i r e c t o r a t e - G e n e r a l $ 2 7 m
HIV & TB Vaccine R&D Funding
HIV/AIDS
$589.9 million Total spend on HIV Vaccine R&D in 2010
HIV & TB Vaccine R&D funding 2007-2010
TB
$81.9 MILLION Total spend on TB Vaccine R&D in 2010
$-
$100
$200
$300
$400
$500
$600
$700
2007 2008 2009 2010
Mill
ion
s
HIV
TB
HIV Vaccine R&D funding – by funder type 2010
Public funding
86%
Philanthropic
funding 12%
Industry funding
2%
Top funders HIV Vaccine R&D, 2010
1 US NIH $414m
2 Bill & Melinda Gates Foundation
$65m
3 USAID $27m
4 US DoD $25m
5 Industry $21m
6 UK DFID $14m
7 European Commission $10m
8 The Wellcome Trust $4m
TB Vaccine R&D funding – by funder type, 2010
Public funding 49%
Philanthropic funding
40%
Industry funding
9%
Other 2% Top funders TB Vaccine R&D, 2010
1 Bill & Melinda Gates Foundation $30m
2 Industry $17m
3 US NIH $15m
4 UK DFID $10m
5 Health Protection Agency $4m
6 European Commission
$4m
of public funding for HIV vaccine R&D came from Science and Technology funding agencies in 2010 of public funding for TB vaccine R&D came from Science and Technology funding agencies in 2010
Science & Technology Vs Aid funding
90%
66%
European public funding of HIV Vaccine R&D
↓$15.8m (-29%) in 2010
$16.7m (-22%) in 2010 From UK
$10.8m (-36%) in 2010 From EC
$-
$10
$20
$30
$40
$50
$60
$70
2007 2008 2009 2010
Mill
ion
s
Norway
Switzerland
France
Sweden
Denmark
Ireland
Netherlands
European Commission
UK
European public funding of TB Vaccine R&D
↓$5.9m (-20%) in 2010
$14.3m (up 21%) in 2010 From UK
$4.0m (-45%) in 2010 From EC
$-
$5
$10
$15
$20
$25
$30
$35
2007 2008 2009 2010
Mill
ion
s
Spain
Sweden
Denmark
Switzerland
Netherlands
European Commission
UK
The HIV and TB vaccine portfolios
Several products moving into expensive late-stage clinical trials
0
5
10
15
20
25
30
HIV Vaccines TB Vaccine
Preclinical
Phase I
Phase II
Phase III
Key messages
Vaccine R&D funding for neglected diseases
• Funding is highly concentrated • Mostly comes from:
• US funders • Public sector • Science and technology budgets
• Funding cuts at a time when several
promising products are entering late stage development
Vaccine R&D funding for neglected diseases
- R&D pipelines need reliable long-term funding
- Financial pressures mean smarter funding will be needed: - Outcome driven and flexible - Aligned with product and portfolio developments - Coordinated - Targeted to deliver the highest health impact
It took a long time and a lot of effort to restart neglected disease vaccine R&D but it is under threat –
The time to act is NOW